Abiomed - ABMD Stock Forecast, Price & News

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Wall Street Analyst Weigh In

Several analysts have commented on ABMD shares. StockNews.com lowered shares of Abiomed from a "buy" rating to a "hold" rating in a research report on Friday, July 1st. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Abiomed from $410.00 to $355.00 in a report on Thursday, July 21st. Finally, Morgan Stanley cut their price objective on shares of Abiomed from $275.00 to $235.00 and set an "underweight" rating on the stock in a report on Friday, July 15th.

Abiomed Price Performance

NASDAQ:ABMD traded down $9.30 during midday trading on Wednesday, hitting $281.82. The company's stock had a trading volume of 349,321 shares, compared to its average volume of 328,503. The firm has a market cap of $12.86 billion, a P/E ratio of 59.46 and a beta of 1.35. Abiomed has a fifty-two week low of $219.85 and a fifty-two week high of $379.30. The firm's 50 day moving average is $266.54 and its 200-day moving average is $282.92.

Abiomed (NASDAQ:ABMD - Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The medical equipment provider reported $1.25 EPS for the quarter, topping analysts' consensus estimates of $1.06 by $0.19. The business had revenue of $277.15 million for the quarter, compared to analysts' expectations of $276.46 million. Abiomed had a net margin of 20.60% and a return on equity of 14.33%. The business's revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the company earned $1.10 EPS. As a group, analysts forecast that Abiomed will post 4.73 EPS for the current year.

Insider Activity

In other news, CFO Todd A. Trapp sold 1,000 shares of the stock in a transaction that occurred on Wednesday, August 3rd. The stock was sold at an average price of $300.00, for a total transaction of $300,000.00. Following the transaction, the chief financial officer now owns 16,927 shares in the company, valued at approximately $5,078,100. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 2.50% of the company's stock.